Re: Thoughts on StockGumShoe....
in response toby
Top-Line Data Expected September 2019 for BETonMACE Phase 3 Cardiovascular Outcomes Trial for Apabetalone
GAC - I agree that RVX attends many conferences without announcing them in a news release. Just trying to guess why this time and only came up with this. We have been after Sarah as to updates on MACE numbers and whether the vague numbers they have given us were ajuducated or not. She has stuck with the line that it has not been released to the public so she wouldn't answer. Maybe this was them finally releasing it to the public. Even though DM did not directly say it, he strongly alluded to them being adjudicated when he said there were about 12 left that the approximate 238 were adjudicated or he wouldn't know how many were left. Although he didn't say it in the NR, there was a hot link in the NR so maybe that makes the whole webcast a part of the NR so the public was properly notified. Rather than just putting out a NR saying there are about 12 left and top line data is expected arounf mid-year, they maybe added the conference notification and webcast to make the most of the NR while at it. Just guessing!